ZelalemTemesgenMDFIDSA, AAHIVS

Infectious Disease • Rochester, MN

HIV/AIDS Medicine, International Health, Travel & Tropical, Mycobacterial Disease

Professor of medicine Director, HIV Program Executive Director, Mayo Clinic Center for Tuberculosis

Join to view full profile

Dr. Temesgen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Temesgen's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Infectious Disease, 1992 - 1995
Central Michigan University College of Medicine/CMU Medical Education PartnersResidency, Internal Medicine, 1989 - 1992
Charles University - Karlova and Hradci Faculty of MedicineClass of 1986

Certifications & Licensure

MN State Medical License 1992 - 2025
MI State Medical License 1991 - 1993
American Board of Internal Medicine Infectious Disease

Clinical Trials

Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Recruiting
Roles: Contact, Principal Investigator
Respiratory Virus Outpatient Study (FLU 002 Plus) Start of enrollment: 2009 Aug 01
Completed

Publications & Presentations

PubMed

114 citations
Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis.
Edison J Cano, Xavier Fonseca Fuentes, Cristina Corsini Campioli, John C. O’Horo, Omar Abu Saleh
Chest. 2021-03-01
219 citations
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Michael J. A. Reid, Nimalan Arinaminpathy, Amy Bloom, Barry R. Bloom, Catharina Boehme
Lancet. 2019-03-30
87 citations
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Richard T. Davey, Eduardo Fernández-Cruz, Norman Markowitz, Sarah Pett, Abdel Babiker
The Lancet. Respiratory Medicine. 2019-09-30

Press Mentions

Humanigen’s Lenzilumab Helps Hospitalized COVID-19 PatientsDecember 6th, 2021
CHEST 2021: CRP Predicts Lenzilumab Response in Covid-19 PatientsOctober 20th, 2021
After 40 Years, HIV Presents Research Problems New and OldJuly 23rd, 2021
Join now to see all

External Links

Mayo Clinic Center for Tuberculosis http://centerfortuberculosis.mayo.edu/
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases http://www.journals.elsevier.com/journal-of-clinical-tuberculosis-and-other-mycobacterial-diseases/